(Q36154083)

12 August 2017

1 reference

title

Bevacizumab--current status and future directions (English)

1 reference

12 August 2017

1 reference

Rachel Midgley

1

1 reference

PubMed ID

15939715

12 August 2017

David Kerr

series ordinal

2

1 reference

12 August 2017

6 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

16

1 reference

12 August 2017

999-1004

1 reference

12 August 2017

7

1 reference

Vascular-specific growth factors and blood vessel formation

12 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

VEGF: an update on biological and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI208

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDI208

1 reference

12 August 2017

1 reference

PubMed ID

15939715